Utility of thyroid transcription factor-1 as a predictor of immune checkpoint inhibition plus chemotherapy in advanced lung adenocarcinoma.

Utility of thyroid transcription factor-1 as a predictor of immune checkpoint inhibition plus chemotherapy in advanced lung adenocarcinoma. - TTF-1 and immunochemotherapy in advanced lung adenocarcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000046901

Enrollment

100

Registered

2022-04-01

Start date

2022-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Lung Adenocarcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients with histologically diagnosed lung adenocarcinoma (2) Patients who received immune checkpoint inhibitors plus chemotherapy for advanced recurrent lung adenocarcinoma (3) Patients whose information can be obtained from the medical record (4) more than 20 years old

Exclusion criteria

Exclusion criteria: (1) Patients who have requested not to participate in this study (2) Patients who are judged ineligible by the principal investigator

Design outcomes

Primary

Measure	Time frame
To compare progression-free survival (PFS) in patients with TTF-1 positive and negative tumors	—

Secondary

Measure	Time frame
To analyze objective response rate (ORR) PFS and overall survival(OS). To compare ORR and OS in patients with TTF-1 positive and negative tumors. To compare ORR, PFS and OS in patients with TTF-1 positive and negative tumors of Hematoxylin-Eosin Stain-diagnosed lung adenocarcinoma and in patients with TTF-1-diagnosed non-small cell lung cancer (NSCLC) favor adenocarcinoma. To compare ORR, PFS and OS in patients with TTF-1 positive and negative tumors for each chemotherapy regimen. To compare ORR, PFS and OS in patients for each PD-L1 expression. To compare ORR, PFS and OS in patients with TTF-1 positive and negative tumors for each PD-L1 expression. To compare TTF-1 positivity rates by histopathology and compare ORR, PFS and OS in patients with TTF-1 positive and negative tumors.	—

Measure

Time frame

To analyze objective response rate (ORR) PFS and overall survival(OS). To compare ORR and OS in patients with TTF-1 positive and negative tumors. To compare ORR, PFS and OS in patients with TTF-1 positive and negative tumors of Hematoxylin-Eosin Stain-diagnosed lung adenocarcinoma and in patients with TTF-1-diagnosed non-small cell lung cancer (NSCLC) favor adenocarcinoma. To compare ORR, PFS and OS in patients with TTF-1 positive and negative tumors for each chemotherapy regimen. To compare ORR, PFS and OS in patients for each PD-L1 expression. To compare ORR, PFS and OS in patients with TTF-1 positive and negative tumors for each PD-L1 expression. To compare TTF-1 positivity rates by histopathology and compare ORR, PFS and OS in patients with TTF-1 positive and negative tumors.

—

Countries

Japan

Contacts

Public ContactJun Yamada

Kobe University Graduate School of Medicine division of respiratory medicine, department of Internal medicine,

jyamada@med.kobe-u.ac.jp0783825660

Outcome results